Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(KFRC, KEYW, CCXI, CRWE) Stock Report


FREE Daily Stock Alerts From


Kforce Government Solutions (KGS), Inc., a wholly-owned subsidiary of Kforce Inc. (Nasdaq:KFRC), reported that the company has entered into a joint research agreement with the University of South Florida (USF) to investigate and innovate new and improved trauma training technologies and methodologies.

The collaborative research activities will be conducted primarily at USF Health's state-of-the-art Center for Advanced Medical Learning and Simulation (CAMLS) in Tampa, FL.


With the technology of the Internet evolving day in and day out, the use of videos for advertise your brand can be effective.

Crown Equity Holdings Inc., (OTCPK:CRWE) recenly launched CRWE Tube,, a video sharing site that allows billions of people around the world to upload, watch and share original videos.

Restricting your marketing to just written text vastly limits your audience; video marketing should be seen as another mode of online communication to reach potential customers.

CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

CRWE‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

More about CRWE at


The KEYW Holding Corporation (Nasdaq:KEYW) reported the completion of the acquisition of Poole & Associates, Inc. (Poole) that was announced on September 10, 2012. As previously noted in our press release on September 10, 2012, the acquisition is expected to be immediately accretive to earnings, subject to final purchase price accounting.

With the closing of this acquisition, KEYW now has over 1,000 employees, more than 800 of which hold at least a Top Secret security clearance.


ChemoCentryx, Inc. (Nasdaq:CCXI) reported preclinical results for CCX872, the Company's next-generation, orally bioavailable inhibitor of the chemokine receptor known as CCR2.

The findings showed that treatment with CCX872 improved multiple parameters of renal function in an in vivo model of diabetic nephropathy.

The data were reported in an oral presentation titled, "CCR2 Inhibition Improves Renal Function in Diabetic BTBR ob/ob Mice," at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) taking place in Berlin.



Disclaimer: publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.